MedTrace Logo

A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine

NCT01159743 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 346

Last updated 2013-01-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the body fat distribution in Human Immunodeficiency Virus-1 (HIV-1) infected patients receiving, since the beginning and for at least two years, an antiretroviral therapy based on efavirenz or lopinavir/ritonavir and a combination of tenofovir plus emtricitabine (or lamivudine).

Conditions

  • HIV Infection

Sponsors & Collaborators

  • Demométrica

    collaborator UNKNOWN

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Angel Burgos, Other · Abbvie Farmaceutica S.L.U. Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01159743 on ClinicalTrials.gov